AP-505

N/A

Report date: 2026/04/06 20:01:48

Base Information

Drug NameAP-505
Drug Alias NameB1962AP-505AP505
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-Vascular endothelial growth factor
TargetsProgrammed death-ligand 1Vascular endothelial growth factor
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAP Biosciences Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTasly Biopharmaceuticals Co LtdAP Biosciences IncTasly Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A